🇺🇸 Alfacalcidiol in United States

16 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Thyroid Stimulating Hormone Increased — 2 reports (12.5%)
  2. Drug Ineffective — 2 reports (12.5%)
  3. Drug Interaction — 2 reports (12.5%)
  4. Fatigue — 2 reports (12.5%)
  5. Thyroid Cancer Metastatic — 2 reports (12.5%)
  6. Thyroxine Free Decreased — 2 reports (12.5%)
  7. Abdominal Pain — 1 report (6.25%)
  8. Angina Pectoris — 1 report (6.25%)
  9. Blood Creatinine Increased — 1 report (6.25%)
  10. Blood Fibrinogen Decreased — 1 report (6.25%)

Source database →

Alfacalcidiol in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Alfacalcidiol approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Alfacalcidiol in United States?

Per Ivarsen is the originator. The local marketing authorisation holder may differ — check the official source linked above.